Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab) (NCT02318901)
There will be two phase II cohorts for pembrolizumab (Keytruda®; Merck & Co., Inc.) plus trastuzumab (Herceptin®;Genentech, Inc.): one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) phase II arm will be for patients with HER2 overexpressing MBC. There will be two phase II cohorts for pembro plus cetuximab (Erbitux®; Eli Lilly and Company.): one cohort will be for patients with HNSCC, the other cohort will be for patients with K-ras, B-raf, N-ras wildtype metastatic CRC.
This trial is sponsored by Western Regional Medical Center. 
- Advanced Cancer
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Colorectal Cancer
- Phase: I & II
- Estimated Enrollment: 90
- Start: October 2014
- Estimated Primary Completion: October 2015
- Last verified: April 2015
Last Editorial review: July 31, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.